Company intelligence / Profile preview

DongKoo Bio & Pharma

Ownership: Private
Employees: ~381
Development stage: Commercial

Overview

Leading Korean derm Rx co.; diversified pipeline including late/pre-clinical assets

Therapeutic areas: CardiovascularMen's HealthRheumatologyEndocrinologyImmunologyDermatology
Modalities: Small moleculesPeptidesStem cell-based ingredients/cosmeceuticals
Industry: Biotech

Partnerships

Moberg Pharma AB—agreement to develop/commercialize MOB‐015 topical treatment for onychomycosis in Korea.Novacell Technology—technology transfer/license agreement related to NCP112/FPR2-targeting peptides.

Beyond the preview

Go deeper on DongKoo Bio & Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DongKoo Bio & Pharma.

Explore the full profile